Entresto (sacubitril/valsartan) 51mg Tablets

Description

Entresto (sacubitril/valsartan) is a prescription medication used to treat congestive heart failure (CHF). It was approved by the Food and Drug Administration (FDA) in July 2015 and is classified as a combination therapy that combines two drugs to improve the outcomes of heart failure.

Entresto is composed of sacubitril and valsartan, which have different mechanisms of action. Sacubitril is a prodrug that is converted to an active metabolite that inhibits the enzyme neprilysin, while valsartan is an angiotensin receptor blocker (ARB) that blocks the action of a hormone (angiotensin II), which causes blood vessels to narrow and raises blood pressure.

Entresto is available as a tablet that is taken orally. The dosage may differ depending on the severity of the heart failure being treated.

Many clinical studies have revealed that Entresto is highly effective in treating heart failure. It improves cardiovascular outcomes, reduces hospitalization for heart failure, and prolongs survival in patients with both reduced and preserved ejection fraction. It also improves exercise tolerance, quality of life, and symptoms of heart failure such as shortness of breath and fatigue.

The effectiveness of Entresto is attributable to its unique mechanism of action, which combines ARB and neprilysin inhibitor. It lowers blood pressure by blocking the hormone angiotensin II and boosts levels of peptides that vasodilate blood vessels and promote sodium excretion. Its mechanism prevents heart muscle cell death and remodeling, and thereby reduces the progression of heart failure.